Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3Tumor-Agnostic 2Thoracic 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Gynecologic 2Sarcoma 1Myeloid 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Breast Neoplasms 1

Interventions

Gemcitabine 218Fluorouracil 142Oxaliplatin 132Capecitabine 122pembrolizumab 113Irinotecan 110Leucovorin 104Bevacizumab 98Nivolumab 80Cisplatin 80130-nm albumin-bound paclitaxel 80Cetuximab 79Radiotherapy 78Albumin-Bound Paclitaxel 59Sorafenib 56Paclitaxel 53Cyclophosphamide 50Carboplatin 47Magnetic Resonance Spectroscopy 44Specimen Handling 39Docetaxel 37Taxes 36fludarabine 34Radiation 34durvalumab 33Ipilimumab 33Erlotinib Hydrochloride 33Biopsy 33Radiosurgery 27Folfox protocol 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × ceralasertib × Gastrointestinal × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡